Cartesian Therapeutics Inc. (RNAC) — Cash Flow Reinvestment Rate

Latest as of September 2024: 0.91x

Cartesian Therapeutics Inc. (RNAC) has a Cash Flow Reinvestment Rate of 0.91x as of September 2024, reinvesting $12.40 Million (capex $6.20 Million plus investments $-6.20 Million) from operating cash flow of $13.69 Million. Explore capital reinvestment ratio of Cartesian Therapeutics Inc. to see what proportion of operating cash flow is directed to capital expenditures.

Reinvestment Rate

0.91x
(Capex + Investments) / Operating CF

Total Reinvested

$12.40 Million
Capex + Investments

Operating Cash Flow

$13.69 Million
USD

Capital Expenditures

$6.20 Million
USD

Cartesian Therapeutics Inc. Cash Flow Reinvestment Rate (2020–2020)

Historical reinvestment intensity for Cartesian Therapeutics Inc. across 1 annual periods. Also explore RNAC total asset value for the complete picture of this company's asset base.

Annual Cash Flow Reinvestment Rate for Cartesian Therapeutics Inc. (2020–2020)

Year-by-year capital reinvestment analysis for Cartesian Therapeutics Inc.. For live market cap and broader valuation context, see Cartesian Therapeutics Inc. market cap and net worth.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2020 0.04x $1.56 Million $34.88 Million $815.00K
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow